Fig. 1
From: Novel CSF β-synuclein-specific assays signal early synaptic degeneration in Alzheimer’s disease
Schematic representation of synuclein proteins (α, β, and γ-synuclein) illustrating their conserved and unique epitopes. The lower panel shows the results of the β-syn-targeting ELISAs: N-terminus assay (using an EP1537Y antibody for detection and N-terminus capture), mid-region assay (utilizing EP1537Y and ADx β-syn1 antibodies), and C-terminus assay (using EP1537Y for detection of ADx β-syn2 for capture). The placement of antibodies reflects their approximate binding sites on the β-syn protein. These in-house β-syn-specific assays offer targeted epitope recognition, enhancing the specificity of synaptic degeneration biomarker detection in AD. The exact binding epitopes of the antibodies are listed in the figure, starting with the first amino acid binding position and ending with the last amino acid